Arvinas Inc.

Transforming the Future for Patients

At Arvinas, we’re reimagining what’s possible in medicine. Our mission is clear: to develop innovative therapies for patients with cancers and other hard-to-treat diseases by targeting the root causes — disease-driving proteins.

We’re leading the way with our proprietary PROTAC® protein degraders (proteolysis-targeting chimeras), a groundbreaking technology that harnesses the body’s natural protein disposal system to remove harmful proteins. This novel approach has the potential to transform treatment outcomes and offer hope where few options exist today.

LEARN MORE ABOUT ARVINAS’ PROTAC DISCOVERY ENGINE

But our impact goes beyond science. At Arvinas, we cultivate a culture of curiosity, purpose, and collaboration. We’re passionate about pushing boundaries and energized by the opportunity to change lives. Whether in the lab or across teams, we celebrate wins, support one another, and thrive on tackling challenges together — all while having fun along the way.

5 Science Park 395 Winchester Ave
New Haven, CT 06511
  • Featured Employer
  • NextGen Class of 2015
Shaping biotech’s future through bold science and strong partnerships
CULTURE
Values Matter at ARVINAS

At Arvinas, our values—pioneering, excellence, community and commitment—guide our most important decisions. And we’re not just saying that – we really mean it. Created through a grassroots initiative driven by our employees, we are always looking for ways to bring our values to life.
OUR VALUES

PIONEERING
We establish new scientific frontiers by challenging the perceived limits of drug discovery and development. We believe that every problem has a solution.

EXCELLENCE
Excellence and execution are the bedrock of everything we do. We ask critical questions and act decisively.

COMMITMENT
We believe that the best ideas emerge in diverse, equitable, and inclusive environments. We are committed to working together, celebrating accomplishments, and encouraging our colleagues through challenges.

COMMUNITY
Our community extends beyond our colleagues at Arvinas and includes patients, their families, and caregivers. We support patients and their advocates by acting with passion, compassion, and urgency.

GIVING BACK

Our Promise to Patients, their Families, and Caregivers Community

At Arvinas, we’re committed to giving back to both the patient communities we aim to serve and the communities in which we live.

Giving back through volunteer groups, nonprofit organizations, charity work, or other means helps those in need and contributes to the common good, while improving the lives of those we are working to help.

It’s not just about raising money. It’s about getting out there and participating in events and meeting the people in our own local communities, as well as those who are affected by the diseases we are working to treat.

Bringing Comfort and Hope Through Art

We partnered with the Foundation for Hospital Art to create bold, beautiful art that was donated to local hospitals and healthcare facilities.

Yale-New Haven Closer to Free Ride

We raised money for the Smilow Cancer Hospital at Yale, just by riding our bikes.


Breast Cancer Awareness Month

We raised funds for Susan G. Komen’s efforts.


Walk to End Alzheimer’s

We participated in the Walk to End Alzheimer’s® at Lighthouse Point Park and raised money for the Alzheimer’s Association.


Biotech Pre-Thanksgiving Bowling Fundraiser

We won the “best t-shirt contest,” but more importantly, we raised money for the children’s hospitals at UCONN and Yale!

BENEFITS

Designed with health and wellness in mind, employees and their families are eligible for:

  • Medical, dental, and vision options, including a generous company contribution into an HSA for the high-deductible plan
  • Paid maternity and paternity leave
  • FSA, HSA, Healthcare, and Dependent Care accounts
  • Company-provided life insurance and short/long-term disability coverage
  • $400 fitness reimbursements for all full-time employees
  • Additional voluntary benefits, including critical illness, hospital care and more

Central to our organization is attracting, retaining, and engaging the best and brightest talent by sharing in the success of our organization:

  • Competitive salaries and an annual performance bonus program
  • 401k matching program with immediate vesting
  • Eligibility for long-term equity incentives upon hire and annually

We also offer professional and career development opportunities that align with our core values of Pioneering and Excellence, including:

  • Situational leadership for People Managers
  • Self-Leadership for Individual Contributors
  • How to manage remote or hybrid teams
  • Interviewing skills
  • Performance feedback
  • Development planning

We believe it’s important to relax, unwind and enjoy life’s special moments:

  • Paid vacation
  • A year-end office closure
  • Observed company holidays
  • Paid sabbatical upon five years’ tenure
NEWS
Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, announced the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer.
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
JOBS
IN THE PRESS